Background: Transplantation of mesenchymal stem cells (MSCs) is a promising therapy for degenerative spine conditions. However, cell therapy for painful spine degeneration presently requires use of contrast agents during fluoroscopy-guided injections, and the effects of these agents on MSCs represents a gap in knowledge. Objective: To investigate the biological effects of contrast media (CM) that are coinjected with MSCs. Design: Prospective observational study. Setting: Academic medical center. Participants: Patient-derived clinical-grade culture expanded MSCs. Interventions: Iohexol (Omnipaque300) was reduced to 12.5%, 25%, 50%, and 100% of the stock solution and incubated with MSCs for 30 minutes, 4 hours, and 48 hours. We also used complete media and 12.5%, 25%, 50%, 100% of phosphate-buffered saline as a control group. Main Outcome Measures: We examined cytotoxicity of iohexol at different concentrations and exposure duration, as well as the potential for recovery over time. Cell counts, mitochondrial activity, and quantitative real time reverse-transcriptase polymerase chain reaction of related genes were analyzed immediately after exposure (day 0) and after 2 days of exposure (day 2). Results: Human MSCs exhibit a time-and concentration-dependent cytotoxic response to iodinated CM. A brief, 30-minute exposure did not affect MSCs function and viability. However, extended treatment with iohexol for 4 hours at 50% or higher concentration had a significant impact on both viability and gene expression in MSCs. Conclusions: Iohexol is cytotoxic to MSCs in a time-and concentration-dependent manner. Hence, the concentration of CM that accompanies MSC injections should be carefully considered during MSC therapy for disk-degenerative diseases. Level of Evidence: III.
Introduction
Degenerative musculoskeletal and spine conditions are significant causes of pain and disability [1] . Advances in regenerative medicine and cell-based therapies, particularly the transplantation of mesenchymal stem cells (MSCs), have inspired numerous studies and resulted in clinical trials using these biological therapies to treat degenerative conditions, often reporting favorable outcomes [2] . A recent clinical trial demonstrated that MSC therapy may be a valid alternative treatment for chronic back pain caused by degenerative disk disease [3] . To validate the safety and utility of MSC therapy for interventional spinal and peripheral joint procedures, it is necessary to address concerns about the potential cytotoxicity of drugs that are coinjected with MSCs.
Among agents that are coinjected with stem cells, iodinated contrast medium (CM) often is used for diagnostic and therapeutic fluoroscopically guided spinal procedures such as endoscopic lumbar diskectomy, intradiskal electrothermal therapy, diskography, facet joint block, chemonucleolysis, or selective nerve root blockade [4] . Although MSC injections in the peripheral joint increasingly are delivered with the use of ultrasound guidance, CM continue to be used in spine procedures, and hence the biological effects of contrast agents on stem cells remain to be explored.
Iohexol is a nonionic, monomeric iodinated contrast agent that has been used routinely to ensure accurate needle placement during fluoroscopically guided spine procedures. However, iohexol may affect the biological properties of human MSCs. We addressed this possible concern because of reports of the cytotoxicity of iodinated CM in various cell types such as renal epithelial cells, endothelial cells, mesangial cells, pulmonary mast cells, smooth muscle cells, and human disk cells [5] [6] [7] [8] . Several studies found that ionic CM was more toxic than nonionic CM due to its ionic strength [5, 9, 10] . Because there are concerns with the cytotoxic effects of iohexol on MSCs, we assessed whether iohexol is cytotoxic for MSCs. One question that arises is whether short-term contact between iohexol and MSCs during injection may negatively affect the long-term viability. Hence, our study investigates the hypothesis that biological effects of short-term treatments ($30 minutes) may have both acute consequences and may last beyond the initial recovery period.
Methods

General Design
This study was designed to study the effects of different dilutional strengths of iohexol. We note that contrast agents are commercially available in various strengths, and it would be clinically useful to study the effects of different premixed concentrations. However, cells in culture cannot be maintained without proper cell culture medium that contains essential physiological nutrients that are required for cell survival. Therefore, to achieve proper biochemical titration of the toxicity of contrast agents on human platelet lysate expanded MSCs in cell culture, it was necessary to perform a dilution series in which agents were mixed with complete cell culture medium at a ratio of 1:4. The experimental arm was exposed to 100%, 50%, 25%, and 12.5% dilutions of Omnipaque 300 (iohexol injection, iodine content 300 mg/mL, NDC 0407-1413-86; GE Healthcare, Chicago, IL) in complete media (Table 1 ). The control arm was exposed to 100%, 50%, 25%, and 12.5% dilutions of phosphatebuffered saline (PBS; Life Technologies, Grand Island, NY) in complete media. We also used complete media (0% Omnipaque and 0% PBS group) as control. Exposure durations were 30 minutes, 4 hours or 48 hours. Cells were analyzed for viability and function immediately postexposure (day 0), or after 48 hours recovery (day 2) after Omnipaque/PBS exposure.
Cell Isolation
After institutional review board approval and informed consent, human MSCs were isolated from lipo-aspirates using previously described methods [11] . In brief, lipoaspirates were digested with Type I collagenase (Worthington Biochemicals, Lakewood, NJ) for 1.5 hours at 37
C, centrifuged at 400 g for 5 minutes, rinsed with PBS, and strained using 70-μm cell strainers (BD Biosciences, San Jose, CA). After this, the aspirate was treated with 154 mM NH 4 Cl, 10 mM KHCO 3 , and 0.1 mM ethylenediaminetetraacetic acid for erythrocyte lysis. The remaining MSCs were expanded in advanced minimum essential medium (Life Technologies), supplemented with 5% (vol/vol) human platelet lysate (PLT Max; Mill Creek Life Sciences, Rochester, MN), 2 mM Glutamax (Life Technologies), 2 U/mL heparin, and 1% Penn-Strep (100 U/mL penicillin, 100 μg/mL streptomycin; Cellgro, Corning, NY). All MSCs used in experimentation were of passage 7. The donor-derived MSCs selected in this study have been shown previously to express standard MSC markers and are capable of multilineage differentiation [12] .
The cells were grown at 37 C in a humidified 5% CO 2 incubator until 90% confluent, were trypsinized (TrypLE Express; Life Technologies), and then were seeded onto 96-well plates (for 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium)
[MTS] analysis), 24-well plates (for 4 0 ,6-diamidino-2-phenylindole [DAPI] and Trypan blue staining analysis), and 6-well plates (for quantitative real time reversetranscriptase polymerase chain reaction [RT-qPCR] analysis) at a density of 10,000 cells/cm 2 . We prepared human MSC suspensions with concentrations of 60,000 or 200,000 cells/mL. We added 50 μL (60,000 cells/mL), 100 μL (200,000 cells/mL), and 500 μL (200,000 cells/mL) of human MSC cell suspensions in each well of a 96-well, 24-well, and 6-well plates, respectively. The cells were cultured for 24-48 hours until they reached a cell density of 90% confluence before experimental treatment.
Treatment Groups
Human MSC cultures were subdivided into triplicate wells per condition and exposed to one of the following dilutions: 100%, 50%, 25%, 12.5% (diluted with complete C in a humidified 5% CO 2 incubator. After the exposure, the cells were washed in 1× PBS solution and returned to the incubator in fresh culture media. MSC viability was measured immediately postexposure (day 0), and also 48 hours (day 2) after treatment. Expression analysis was performed with the 4 hours exposure group.
Assessment of MSC Viability
To assess cell viability and proliferation potential after contrast exposure, two cell counting methods were used: Trypan Blue (Sigma-Aldrich, St. Louis, MO) and DAPI staining. Twenty microliters of trypsinized cells were mixed with 20 μL of 0.4% Trypan Blue solution and incubated for 3 minutes at room temperature. Ten microliters of that solution was then transferred to a dual-chamber hemocytometer, and the cells were counted using conventional light microscopy. Trypan Blue does not stain living cells because their membranes remain intact. Cell viability was calculated as the fraction of viable cells (number of unstained cells) divided by the total number of cells (number stained and unstained cells) and multiplied by × 100% [13] .
We also used DAPI staining (Life Technologies) paired with Image J analysis, an open-source National Institutes of Health-supported image analysis software program to count the cell number. Images were acquired using an inverted light microscope (Zeiss, Cambridge, MA). DAPI is a fluorescent stain that binds strongly to A-Trich regions in DNA. As DAPI can pass through an intact cell membrane, it can be used to stain both live and fixed cells, although it passes through the membrane less efficiently in live cells and therefore the effectiveness of the stain is lower. In our study, we used 0.1% triton to permeabilize the fixed cells, so we also easily stained the live cells.
To assess the metabolic activity of MSCs after contrast exposure, MTS colorimetric assays (Promega, Madison, WI) were performed at day 0 and 48 hours after exposure. MTS assays were read using a Spectra Max plus Plate Reader (Molecular Devices, Sunnyvale, CA) at an absorbance wavelength of 490 nm. The assay is based on the reduction of MTS tetrazolium compound by viable cells to generate a colored formazan product that is soluble in cell culture media. This conversion is carried out by mitochondrial nicotinamide adenine dinucleotide phosphate-dependent dehydrogenase enzymes in metabolically active cells. The formazan dye produced by viable cells can be quantified by measuring the absorbance at 490 nm and reflects cell metabolic activity. All of the samples were assayed in triplicate.
Expression Analysis of Human MSCs in Response to Omnipaque Exposure
To assess the effect of Omnipaque exposure on cell activity and behavior, human MSCs were subjected to RTqPCR analysis, with genes widely recognized as associated with cell proliferation, stress response, and stem cell surface markers (Table 2 ). Before RT-qPCR, RNA was isolated using the miRNeasy Mini Kit (QIAGEN, Hilden, Germany) and total RNA yield was evaluated using the Nanodrop 2000 UV-Vis Spectrophotometer (Thermo Fisher Scientific, Inc, Waltham, MA). Reverse-transcriptase was then performed to obtain cDNA using Super Script III reverse transcriptase (Invitrogen, Carlsbad, CA). The resulting cDNAs were used in RT-qPCR (CFX384 Real-Time System; BioRad, Hercules, CA) using SYBR Green detection with primers that detect select biomarkers for stress responses and/or proliferation (early growth response transcription factors [EGR] 1, 2), stress responses (activating transcription factor [ATF] 4, 6), and stem cell surface markers (CD90, CD105). Primer sequences are listed in Table 2 . Gene expression levels were quantified using the 2 −ΔΔ Ct method. Values for mRNA expression were normalized to the housekeeping gene GAPDH.
Statistical Analysis
Descriptive statistics were used to demonstrate the effects of contrast exposure on human MSC cell counts (ie, viability), mitochondrial activity and qPCR on days 0 and 2 after exposure. Results were analyzed by 1-way or 2-way analysis of variance as appropriate, and unpaired Student's t-test. Statistical significance was set at 
Results
Effects of Omnipaque on Live/Dead Cell Counts and Proliferative Ability of MSCs
Our study addresses the hypothesis that contrast agents may have biological effects on stem cells. Omnipaque is the most common contrast agent for interventions in spine and is available as injection solutions of different strengths (ie, 180, 240 and 300 mg/mL). Therefore, we tested how different concentrations of Omnipaque affect the viability of stem cells at different concentrations.
Live/dead cell analysis by Trypan Blue staining is shown in Figure 1A -B. MSC viability did not show significant decrease with 30-minute exposure to any concentration of CM, indicating that short exposure of MSCs to CM is well tolerated even at high concentrations. MSC viability decreased with exposure to 100% Omnipaque after 4-hour exposure, and with exposure to either 50% or 100% Omnipaque after 48 hours exposure (P < .05, Figures 1A and 2B ).
Although our results showed that the presence of Omnipaque affects the cellular integrity of MSC, we reasoned that subsequent removal of the Omnipaque may restore the normal biological properties of the cells after a recovery of 2 days. The results show that cells incubated with CM at concentrations of stronger than 50% do not adequately recover.
Proliferative ability was assessed by cell counting after DAPI staining, which showed that viable cell numbers of human MSC's decreased only in 100% Omnipaque concentration after 4 hours of exposure and in 25%, 50%, 100% Omnipaque concentrations after 48 hours' exposure when cells were immediately analyzed without a recovery period (ie, day 0). Meanwhile, the viability of human MSCs decreased in 50% and 100% Omnipaque concentration after either 4 or 48 hours of exposure groups after recovery for 2 days in culture (day 2, P < .05, Figure 2A-B) . Hence, cell viability is compromised immediately after exposure to Omnipaque and does not recover even after 2 days.
Effect of Omnipaque on Mitochondrial Activity of MSCs
There was no statistically significant effect of 30 minutes of Omnipaque exposure on MTS absorbance at either day 0 or 2. This result suggests that 30 minutes of treatment does not affect mitochondrial activity as an indicator of both the metabolic activity and viability of human MSCs. When samples were immediately analyzed without recovery time (day 0), MTS absorbance decreased after 4 hours of exposure with Omnipaque concentrations of 25%, 50%, and 100%, whereas it decreased after 48 hours with slightly lower Omnipaque concentrations of 12.5%, 25%, 50%, and 100%. For comparison, after a 2-day recovery period (day 2), we observed that MTS absorbance still decreased after 4 hours of exposure in 100% Omnipaque and decreased at concentrations of 25%, 50%, and 100% Omnipaque after 48 hours of exposure (P < .05, Figure 3A -B).
Effect of Omnipaque on mRNA Expression in MSCs
To investigate the molecular events that are triggered by Omnipaque exposure, we measured expression for a number of genes that are indicative of stress responses and/or cell proliferation during a 48-hour time course after initial exposure of 4 hours to Omnipaque exposure. We observed that the early growth responsive transcription factors EGR1 and EGR2 decreased immediately after exposure to a range of concentrations (respectively, 12.5%-100% and 25%-100%). We attribute this initial decrease in EGR1 and EGR2 primarily to their roles in cell-cycle progression of human MSCs, and thus that their diminished mRNA levels reflect suppression of cell proliferation immediately after Omnipaque exposure. Reassuringly, the levels of EGR1 and EGR2 began to increase even after exposure to 100% Omnipaque and subsequently recovered for 2 days in normal growth media (day 2). MSCs subjected to our test conditions expressed very robust levels of genes normally associated with response to endoplasmic reticulum stress and cytoprotective mechanisms, including ATF-4 [14] and ATF-6 [15] . The robust expression of ATF-4 and ATF-6 observed at the time of harvest (day 0) subsided after subsequent culture in growth medium (day 2). Examination of mRNA levels for 2 representative MSC surface markers (CD90 and CD105) revealed an increase in their expression on day 0 and decrease on day 2 after exposure ( Figure 4A-B) . This finding is consistent with a general decrease in expression of cell surface genes when MSCs initiate a phase of active proliferation [10] .
Discussion
This is the first study to examine the impact of different concentrations and exposure times of nonionic iodinated contrast Omnipaque on the viability and function of in vitro, culture expanded human MSCs. The most important finding of the current investigation is that the viability, proliferative capacity and metabolic activity of MSCs are compromised after Omnipaque exposure in a concentration-and time-dependent manner. This cytotoxic effect does not occur after a brief 30 minutes of exposure but is evident after longer exposures to Omnipaque. This time-dependent effect may need to be considered when using Omnipaque in clinical settings in which MSCs are used for regenerative cell therapies.
Omnipaque is a nonionic, iodinated CM commonly used for various intradiskal procedures such as in diskography and endoscopic spinal surgery. In cell culture studies using kidney [5, 16] and lumbar disk cells [4] , ionic contrast agents were significantly more cytotoxic than nonionic contrast dyes. The latter has raised our concerns whether contrast dyes would have similar negative effects on human MSCs. Recently, Chee et al [17] found that iohexol is less cytotoxic as contrast agent than iopamidol that is also a nonionic iodinated contrast agent for intervertebral disk cells. In our studies with human MSCs, we did not test the cytotoxicity of ionic contrast dyes but restricted our analysis to iohexol (Omnipaque 300), the agent that is widely used in fluoroscopically guided injections into the spine and peripheral joints.
Centeno et al [18] found that the viability of bone marrow-derived MSCs decreased only for the 80 mg/mL Omnipaque concentration after 4 hours exposure. As we know, it is the first report about the cytotoxicity of CM to human MSCs. However, there are several limitations in this study. First, there is little synovial fluid in normal and degenerative intervertebral disk, suggesting that the CM concentration in the local injection site probably very high. Centeno et al's "high dose" is not high enough to mimic the situation in disk; second, the evaluation index for cell viability and response to CM exposure is limited.
Omnipaque's active ingredient is iohexol. Edwards et al [19] found that iohexol is eliminated from peripheral joints after approximately 3 hours. However, there are no published data for Omnipaque clearance from the intervertebral disk. Clinical experience suggests a longer half-life than for the knee, as patients are routinely imaged several hours after lumbar diskography with contrast still visible on computed tomography scan [20] . Meanwhile, there is little synovial fluid in normal and degenerative intervertebral disk, suggesting that the CM concentration in the local injection site probably very high. Importantly, our study used a 100% concentration of Omnipaque that was mixed together with human platelet lysate expanded MSCs in complete media with a volume ratio of 4:1. Thus, the final highest Omnipaque concentration is 80% (with final highest iodine content of 240 mg/mL). Our data indicate that this concentration clearly affects the biological properties of MSCs after 4 hours of exposure. Specifically, live/dead cell analysis by Trypan Blue staining showed that the viability of human MSCs decreases not only at a 100% concentration (effective concentration 80% due to mixing) after 4 hours exposure but also at concentrations of 50% and 100% after 48 hours of exposure. Hence, cytotoxicity of Omnipaque is both time and dose-dependent. Interestingly, MTS analysis showed that mitochondrial activity of human MSCs decreases for a range of concentrations (ie, 25%-100%) after only 4 hours of exposure when cells are immediately analyzed, and an even broader range when analyzed after 48 hours of exposure (ie, 12.5%-100%). Therefore, it appears that the metabolic activity of human MSCs is more sensitive and also concentration and time dependent.
Because metabolic activity is pre-requisite for cell proliferation, the MTS results provide a sensitive index for evaluating cell cytotoxicity that complements live/dead cell analysis. We note that metabolic activity decreased after 4 hours' exposure to 50% Omnipaque and returned to normal levels after 2-day recovery in culture. These results have 2 possible ramifications for clinical practice. First, to retain activity and viability human MSCs, the highest dose and exposure to be considered is 50% Omnipaque for 4 hours. Second, it may be beneficial to extend the treatment intervals between diskography and stem cell injection therapy for disk degeneration. Although our focus was not on the joint, based on the reported kinematics of Omnipaque washout in joints, Omnipaque used at concentrations of less than 50% would not be expected to appreciably affect MSCs.
Reduced cell viability upon Omnipaque exposure is consistent with our observation that human MSCs mount a cellular stress/cytoprotective response based on expression of several factors (ie, EGR1, EGR2, ATF4 and ATF6). Expression of EGR1 and EGR2 decreased immediately after Omnipaque exposure (day 0) and increased after recovery in normal cell culture medium (day 2). This finding indicates that cell-cycle progression of human MSCs is acutely suppressed after Omnipaque exposure, but that cell proliferation can resume within 2 days in culture. Robust expression of ATF4 and ATF6, which are genes normally associated with response to endoplasmic reticulum stress and cytoprotective mechanisms, was observed at the time of harvest (day 0) and subsided by day 2. Stresses that trigger this response in mammals can include low temperature, hypoxia, ischemia, and oxidative stress [21] . To mitigate potential contributions from endoplasmic reticulum stress that can enhance expression of ATF, future studies may consider using biocompatible protective scaffolding (eg, alginate) to mitigate the consequences of Omnipaque exposure.
CD90 and CD105 are well-established cell surface markers that are used to characterize multi-potent adult MSCs [22] . Especially during stress conditions (eg, hypoxia), CD105 gene expression is upregulated and is this may attenuate cell apoptosis [23] . CD90 and CD105 on the cell surface of MSCs are down regulated after differentiation [24, 25] . In our study, CD105 expression was upregulated at day 0 culture. One interpretation of this result is that expression is upregulated as part of the stress response. Future studies will be required to confirm whether the stem cell phenotype of MSCs changes after Omnipaque exposure in view of our observation that both CD90 and CD105 were down regulated after short term culture (day 2).
Factors other than osmolality may contribute to the toxic effects of Omnipaque. Ionicity and/or molecular structure (monomeric or dimeric) may be of importance.
Romano et al [26] found that there was no difference in the extent of cell injury between low-osmolality and iso-osmolality CM. Ionic monomeric CM was the most hyperosmolar and was ultimately the most detrimental to cellular viability. Recently, Kim et al [5] used mannitol as a nonionic hyperosmolarity control and found that it had the least toxic influence on human disk cell viability. This indicates that hyperosmolarity alone cannot explain results that ionic monomeric CM is the most detrimental to cellular viability. Rather other physicochemical or biological parameters may dictate sensitivity of MSCs to Omnipaque.
We acknowledge several limitations of the current study that should be considered in the interpretation of the results. First, in vitro cytotoxicity may not adequately reflect in vivo conditions. The cytotoxicity of Omnipaque may differ according to the local environment, including the difference between cultured cells and cells in tissue, the integrated milieu of multiple cell types and tissues, as well as the state of joint or disk degeneration that may alter the pharmacokinetic properties of Omnipaque and/or the cellular response of cells to this contrast agent. Second, we examined in vitro cytotoxicity at stable concentrations over 2 days; although in vivo the Omnipaque concentration may gradually decrease over time, for example, by chemical breakdown or dissipation from the tissue. Although our study conclusively shows that high doses of iohexol have irreversible cytotoxic effects on MSCs in cell culture after 4 hours of treatment, these effects are very concentration and time dependent. No significant effects are observed at 30 minutes, which is a time period more relevant to the clinical setting. Also, dilution of iohexol suffices to mitigate these deleterious effects on MSCs. Furthermore, unlike cell culture studies in which iohexol is in continuous contact with cells, it will dilute and dissipate on injection in patients. Yet, we note that the use of iohexol in intervertebral disks may remain problematic because the compound may neither be diluted nor able to dissipate rapidly. Finally, although stem cell therapies for spine degeneration remain dependent on the use of contrast agents to ensure proper cell delivery, stem cell therapy involving peripheral joints is increasingly performed with ultrasound guidance and thus contrast agents are less of a concern in this practice.
We cultured MSCs with supportive growth media, which may have been more beneficial to them than the adverse environment of a joint or disk into which they might be injected. Hence, the next logical steps in experimentation are studies that examine the effects of human MSCs in explant culture systems ex vivo or in animal models in vivo.
Conclusion
The current in vitro study suggests that iohexol (Omnipaque 300) has direct time-and concentrationdependent cytotoxic effects on human MSCs. The in vitro differences in cytotoxicity study will serve as a foundation for future studies on the biological consequences of contrast media exposure in human MSC, as well as the optimization of CM concentration and treatment intervals between diskography and MSC injection therapy for spine degeneration. Although we believe that iohexol could be avoided out of an abundance of caution, it appears safe for clinical procedures that necessitate the use of contrast agents in cell therapy. We recommend that if contrast agents are coinjected, that the lowest concentration will be used that ensures sufficient contrast. We also advise against pre-mixing because lengthy exposure of MSCs to contrast agents is not optimal for cell viability and as such may reduce the active dose of cells delivered during therapy.
